Altered network efficiency in isolated REM sleep behavior disorder: A multicentric study is a research paper published in Alzheimer s & Dementia (2025). On theSindex it has a DataRank of 0. It has been cited 2 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Agentura Pro Zdravotnický Výzkum České Republiky
Grant: NU21‐04‐00535
Agence Nationale de la Recherche
Grant: ANR‐11‐INBS‐0006
Parkinson Canada
Grant: 2023‐0000000122
Parkinson's UK
Grant: J‐2101
Parkinson Society Canada
Grant: PPG‐2023‐0000000122
Parkinson Canada
Grant: 2023-0000000122
Programme d'investissements d'avenir
Grant: ANR-10-IAIHU-06
Agence Nationale de la Recherche
Grant: ANR-11-INBS-0006
Alzheimer Society Canada
Grant: 0000000082
Parkinson's UK
Grant: J-2101
National Institute for Neurological Research
Grant: LX22NPO5107
Paris Institute of Neurosciences - IHU
Grant: IAIHU-06
Czech Health Research Council
Grant: NU21-04-00535
Parkinson Society Canada
Grant: PPG-2023-0000000122
the Paris Institute of Neurosciences
Grant: IHU (IAIHU-06)
Canadian Institutes of Health Research
Grant: unidentified
unidentified
Control-PD (Joint Programme-Neurodegenerative Disease Research [JPND] Cognitive Propagation in Prodromal Parkinson's disease)
Institut de France to Isabelle Arnulf (for the ALICE Study)
European Union - Next Generation EU
Fonds de recherche du Québec - Santé (FRQ-S)
Michael J. Fox Foundation for Parkinson's Research
Société Française de Médecine Esthétique (M. Legrand)
Canada Research Chair in Cognitive Decline in Pathological Aging
Financed by European Union - Next Generation EU
Genentech Inc., Sanofi Genzyme, Servier, Takeda Pharmaceutical Company, Teva Neuroscience, Inc., UCB, Vanqua Bio, Verily Life Sciences, Voyager Therapeutics, Inc., and Yumanity Therapeutics, Inc
National Institute for Health Research (NIHR)
Parkinson's UK, the Oxford Biomedical Research Centre, CPT, EPND, and the Michael J. Fox Foundation
4D Pharma, AbbVie Inc., AcureX Therapeutics, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson's (ASAP), Avid Radiopharmaceuticals, Bial Biotech, Biogen, BioLegend, Bristol Myers Squibb, Calico Life Sciences LLC, Celgene Corporation, DaCapo Brainscience, Denali Therapeutics, The Edmond J. Safra Foundation, Eli Lilly and Company, GE Healthcare, GlaxoSmithKline, Golub Capital, Handl Therapeutics, Insitro, Janssen Pharmaceuticals, Lundbeck, Merck & Co., Inc., Meso Scale Diagnostics, LLC, Neurocrine Biosciences, Pfizer Inc., Piramal Imaging, Prevail Therapeutics, F. Hoffmann-La Roche Ltd
CIHR, Michael J. Fox Foundation, NIH, Roche Diagnostics, and the Weston Foundation
Fonds Saint-Michel
Michael J. Fox Foundation
National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC)
Électricité de France (Fondation d'Entreprise EDF)
W. Garfield Weston Foundation
Canadian Institutes of Health Research (CIHR)
Fonds de recherche du Québec - Santé, the Canadian Institutes of Health Research, the W. Garfield Weston Foundation, the Michael J. Fox Foundation for Parkinson's Research, and the National Institutes of Health
NIHR Oxford Biomedical Research Centre (BRC)
National Institute for Health and Care Research (NIHR) Oxford Health Clinical Research Facility and the NIHR Oxford Biomedical Research Centre
Control-PD (JPND Cognitive Propagation in Prodromal Parkinson's Disease)
Fondation Thérèse et René Planiol
NIHR Oxford Health Clinical Research Facility
Parkinson's disease from Energipole (M. Mallart)
Fields of Study
MeSH Terms
Keywords